{"disease":{"id":"erosive-esophagitis","name":"Erosive esophagitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":16,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"omeprazole","indication_name":"Erosive esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prilosec","generic_name":"omeprazole","company_name":"AstraZeneca (originally Astra AB)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"Proton pump inhibitor (PPI)","quality_score":50,"revenue":"1041.0","mechanism":"Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) in gastric parietal cells, potently suppressing stomach acid secretion."},{"drug_id":"omeprazole","indication_name":"Maintenance of Healing Erosive Esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prilosec","generic_name":"omeprazole","company_name":"AstraZeneca (originally Astra AB)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"Proton pump inhibitor (PPI)","quality_score":50,"revenue":"1041.0","mechanism":"Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) in gastric parietal cells, potently suppressing stomach acid secretion."},{"drug_id":"dexlansoprazole","indication_name":"Maintenance of Healing Erosive Esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexilant","generic_name":"DEXLANSOPRAZOLE","company_name":"Takeda","drug_phase":"marketed","molecular_target":"(H+, K+)-ATPase","drug_class":"Proton Pump Inhibitor [EPC]","quality_score":67,"revenue":"300","mechanism":"Dexlansoprazole inhibits gastric acid secretion by blocking the (H+, K+)-ATPase enzyme, known as the proton pump, in gastric parietal cells."},{"drug_id":"dexlansoprazole","indication_name":"Erosive esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexilant","generic_name":"DEXLANSOPRAZOLE","company_name":"Takeda","drug_phase":"marketed","molecular_target":"(H+, K+)-ATPase","drug_class":"Proton Pump Inhibitor [EPC]","quality_score":67,"revenue":"300","mechanism":"Dexlansoprazole inhibits gastric acid secretion by blocking the (H+, K+)-ATPase enzyme, known as the proton pump, in gastric parietal cells."},{"drug_id":"dexlan","indication_name":"Maintenance of Healing Erosive Esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dexlan","company_name":"Chang Gung Memorial Hospital","drug_phase":"phase_1","molecular_target":"Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase","drug_class":"","quality_score":7,"revenue":null,"mechanism":""},{"drug_id":"famotidine","indication_name":"Erosive esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pepcid","generic_name":"famotidine","company_name":"Generic (originally Yamanouchi/Merck)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Competitively blocks histamine H2 receptors on gastric parietal cells, reducing basal and stimulated acid secretion."},{"drug_id":"dexilant","indication_name":"Erosive esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dexilant","company_name":"Genuine Research Center, Egypt","drug_phase":"marketed","molecular_target":"Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"dexilant","indication_name":"Maintenance of Healing Erosive Esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dexilant","company_name":"Genuine Research Center, Egypt","drug_phase":"marketed","molecular_target":"Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prevacid","indication_name":"Erosive esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prevacid","company_name":"Vanderbilt University Medical Center","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"esomeprazole","indication_name":"Erosive esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nexium","generic_name":"esomeprazole","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"Proton pump inhibitor (PPI)","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"esomeprazole","indication_name":"Maintenance of Healing Erosive Esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nexium","generic_name":"esomeprazole","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"Proton pump inhibitor (PPI)","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"pantoprazole","indication_name":"Erosive esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Protonix","generic_name":"pantoprazole","company_name":"Generic (originally Byk Gulden/Altana/Nycomed)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1","drug_class":"Proton pump inhibitor (PPI)","quality_score":58,"revenue":null,"mechanism":"Irreversibly inhibits the gastric proton pump (H+/K+ ATPase), suppressing stomach acid secretion."},{"drug_id":"pantoprazole","indication_name":"Maintenance of Healing Erosive Esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Protonix","generic_name":"pantoprazole","company_name":"Generic (originally Byk Gulden/Altana/Nycomed)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1","drug_class":"Proton pump inhibitor (PPI)","quality_score":58,"revenue":null,"mechanism":"Irreversibly inhibits the gastric proton pump (H+/K+ ATPase), suppressing stomach acid secretion."},{"drug_id":"protonix-iv","indication_name":"Erosive esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pantoprazole Sodium","generic_name":"Pantoprazole Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"(H+, K+)-ATPase enzyme","drug_class":"Proton pump inhibitor (PPI)","quality_score":69,"revenue":null,"mechanism":"Pantoprazole suppresses gastric acid by covalently binding the (H+, K+)-ATPase enzyme at parietal cells."},{"drug_id":"protonix-iv","indication_name":"Maintenance of Healing Erosive Esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pantoprazole Sodium","generic_name":"Pantoprazole Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"(H+, K+)-ATPase enzyme","drug_class":"Proton pump inhibitor (PPI)","quality_score":69,"revenue":null,"mechanism":"Pantoprazole suppresses gastric acid by covalently binding the (H+, K+)-ATPase enzyme at parietal cells."},{"drug_id":"rabeprazole-40-mg","indication_name":"Erosive Esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rabeprazole 40 mg","generic_name":"rabeprazole-40-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"H+/K+ ATPase","drug_class":"Proton Pump Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"rabeprazole-40-mg","indication_name":"Erosive Esophagitis in Pediatric Patients 1 to 11 Years Old","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rabeprazole 40 mg","generic_name":"rabeprazole-40-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"H+/K+ ATPase","drug_class":"Proton Pump Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"nizatidine","indication_name":"Erosive esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axid Ar","generic_name":"NIZATIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H2 receptor","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"omeprazol","indication_name":"Erosive esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omeprazol","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"omeprazol","indication_name":"Maintenance of Healing Erosive Esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omeprazol","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pantoprazol","indication_name":"Erosive esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pantoprazol","company_name":"Northern Orthopaedic Division, Denmark","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pantoprazol","indication_name":"Maintenance of Healing Erosive Esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pantoprazol","company_name":"Northern Orthopaedic Division, Denmark","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dexrabeprazole","indication_name":"Erosive esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexpure","generic_name":"dexrabeprazole","company_name":"","drug_phase":"unknown","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Proton Pump Inhibitors","quality_score":null,"revenue":null,"mechanism":"Dexpure works by irreversibly inhibiting the H+/K+ ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"lansoprazole","indication_name":"Erosive esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevacid","generic_name":"lansoprazole","company_name":"Generic (originally Takeda)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"Proton pump inhibitor (PPI)","quality_score":null,"revenue":null,"mechanism":"Irreversibly inhibits the gastric proton pump to suppress acid secretion."},{"drug_id":"dexrabeprazole","indication_name":"Maintenance of Healing Erosive Esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexpure","generic_name":"dexrabeprazole","company_name":"","drug_phase":"unknown","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Proton Pump Inhibitors","quality_score":null,"revenue":null,"mechanism":"Dexpure works by irreversibly inhibiting the H+/K+ ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"ranitidine","indication_name":"Erosive esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zantac","generic_name":"ranitidine","company_name":"GSK (originally Glaxo)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor","drug_class":"H2 receptor antagonist","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"dexlan","indication_name":"Erosive esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dexlan","company_name":"Chang Gung Memorial Hospital","drug_phase":"phase_1","molecular_target":"Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase","drug_class":"","quality_score":7,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":27,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05587309","title":"A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1250,"lead_sponsor_name":"Braintree Laboratories","has_results":false},{"nct_id":"NCT04124926","title":"Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1027,"lead_sponsor_name":"Phathom Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02388737","title":"Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":703,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT06778824","title":"Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.","phase":"NA","overall_status":"RECRUITING","enrollment_count":610,"lead_sponsor_name":"Hualien Tzu Chi General Hospital","has_results":false},{"nct_id":"NCT02388724","title":"Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":481,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04341428","title":"Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":406,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT05890001","title":"A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Braintree Laboratories","has_results":false},{"nct_id":"NCT04022096","title":"Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Esophagitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":351,"lead_sponsor_name":"HK inno.N Corporation","has_results":false},{"nct_id":"NCT03006874","title":"Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":302,"lead_sponsor_name":"HK inno.N Corporation","has_results":false},{"nct_id":"NCT05443984","title":"JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Onconic Therapeutics Inc.","has_results":false},{"nct_id":"NCT03736369","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":263,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT03615677","title":"Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":261,"lead_sponsor_name":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","has_results":false},{"nct_id":"NCT05055128","title":"A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":248,"lead_sponsor_name":"Cinclus Pharma AG","has_results":true},{"nct_id":"NCT06720610","title":"Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":216,"lead_sponsor_name":"Indonesia University","has_results":false},{"nct_id":"NCT02679508","title":"Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04888819","title":"Treatment Effect According to Timing of Administration of DWP14012 40 mg","phase":"NA","overall_status":"UNKNOWN","enrollment_count":186,"lead_sponsor_name":"Konkuk University Medical Center","has_results":false},{"nct_id":"NCT04613895","title":"Treatment Effect According to Timing of Administration of DWP14012 40 mg","phase":"NA","overall_status":"UNKNOWN","enrollment_count":186,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT03943992","title":"Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":170,"lead_sponsor_name":"Yooyoung Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04252144","title":"Study of Dietary Patterns and Food Diversity in Russian GERD Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Russian Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04255693","title":"Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence","phase":"NA","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Federal State Budgetary Scientific Institution \"Federal Research Centre of Nutrition, Biotechnology","has_results":false},{"nct_id":"NCT06939465","title":"Cognitive-behavioral Therapy for the Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Hualien Tzu Chi General Hospital","has_results":false},{"nct_id":"NCT02615184","title":"A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":76,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05267613","title":"Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02873702","title":"Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":37,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT07278349","title":"Bioequivalence Study to Compare Vonoprazan 20 mg Film Coated Tablets Versus Voquezna® 20 mg (Vonoprazan) Tablets","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Humanis Saglık Anonim Sirketi","has_results":false},{"nct_id":"NCT05050188","title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Jiangsu Carephar Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06391177","title":"A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Phathom Pharmaceuticals, Inc.","has_results":true}],"total":27},"guidelines":[{"drug_id":"protonix-iv","guideline_body":"FDA label","recommendation":"Pantoprazole Sodium for Injection is indicated for the treatment of gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"protonix-iv","guideline_body":"FDA label","recommendation":"Pantoprazole Sodium for Injection is indicated for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"protonix-iv","guideline_body":"FDA label","recommendation":"Pantoprazole Sodium for Injection is indicated for the treatment of gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"protonix-iv","guideline_body":"FDA label","recommendation":"Pantoprazole Sodium for Injection is indicated for the maintenance of healing of erosive esophagitis.","line_of_therapy":"maintenance","evidence_grade":"A","guideline_year":null},{"drug_id":"protonix-iv","guideline_body":"FDA label","recommendation":"Pantoprazole Sodium for Injection is indicated for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"omeprazole","guideline_body":"FDA label","recommendation":"Omeprazole is used to treat erosive esophagitis.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"protonix","guideline_body":"FDA label","recommendation":"Pantoprazole Sodium for Injection is indicated for the maintenance of healing of erosive esophagitis.","line_of_therapy":"maintenance","evidence_grade":"not specified","guideline_year":null},{"drug_id":"protonix","guideline_body":"FDA label","recommendation":"Pantoprazole Sodium for Injection is indicated for the treatment of gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"protonix","guideline_body":"FDA label","recommendation":"Pantoprazole Sodium for Injection is indicated for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"protonix","guideline_body":"FDA label","recommendation":"Pantoprazole Sodium for Injection is indicated for the treatment of gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"protonix","guideline_body":"FDA label","recommendation":"Pantoprazole Sodium for Injection is indicated for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}